Project Grant R01HL180393
Award Date 8/18/25
Completion Date 5/31/29
Dollars Obligated $696K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- This federal Project Grant award for $680,583 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Mayo Clinic to discover genetic modifiers and therapies for anthracycline-induced cardiotoxicity, a major side effect of certain chemotherapies. The grant funding will be used to continue studying two previously identified genetic modifier genes, FABP7 and GPNMB, and test the hypothesis that their cardioprotective effects are related...
- This federal Project Grant award, valued at $768,567.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on September 15, 2025, supports research on the use of the PET imaging tracer 68Ga-GALMYDAR to detect cardiotoxicity induced by chemotherapeutic agents like doxorubicin. The award recipient, The Washington University, will conduct in vitro and in vivo studies to evaluate the potential of this novel imaging biomarker to provide an...
- This federal Project Grant award, valued at $425,505 and awarded on September 15, 2025, supports research conducted by Louisiana State University Health Sciences Center-Shreveport focused on the role of cell-specific programmed death-ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The research, funded under the National Institutes of Health's Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the underlying mechanisms of immune-related...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,500.00 to Chapman University to develop peptide-doxorubicin conjugates that can mitigate the cardiotoxicity and overcome drug resistance associated with the chemotherapy drug doxorubicin. The 3-year project aims to investigate the mechanisms by which five peptide-doxorubicin conjugates can selectively target and kill drug-resistant cancer cells while reducing toxicity to...
- This $697,952 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the molecular mechanisms underlying cardiotoxicity caused by the tyrosine kinase inhibitor (TKI) drug osimertinib. The research aims to establish a mouse model for this condition and identify the role of the MYLK3 gene in mediating the observed contractile dysfunction in human induced pluripotent stem cell-derived cardiomyocytes...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
- The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $818,625 to Beth Israel Deaconess Medical Center (BIDMC) to conduct a randomized clinical trial evaluating the use of dexrazoxane and liposomal doxorubicin as cardioprotective strategies for patients with diffuse large B-cell lymphoma who have pre-existing cardiomyopathy or prior anthracycline exposure. The study aims to determine which cardioprotective approach is most effective at...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $552,318 in funding to The Medical College of Wisconsin, Inc. to conduct research on the use of carbonic anhydrase as a cardioprotective target against anthracycline-induced cardiotoxicity. The project aims to leverage human induced pluripotent stem cell-derived cardiomyocytes and CRISPR interference/activation genetic screens to investigate the...
- This federal Project Grant award, valued at $701,842, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research conducted by the University of South Florida to investigate the molecular mechanisms by which mutations in the CDK13 gene lead to congenital heart defects and associated developmental disorders. The project aims to develop mouse and induced pluripotent stem cell (iPSC) models...